OncoSec to Present at the 31st Annual ROTH Conference

Mar 13, 2019 8:30am EDT

OncoSec Announces Poster Presentation at 2019 American Association for Cancer Research Annual Meeting

Feb 28, 2019 8:00am EST

OncoSec To Present At BIO CEO & Investor Conference

Feb 08, 2019 8:00am EST

OncoSec Provides KEYNOTE-695 Clinical Update And Outlines 2019 Milestones

Feb 01, 2019 8:00am EST

OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019

Jan 22, 2019 8:00am EST

OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO™ with Standard of Care KEYTRUDA® for Treatment of Late Stage Cervical Cancer

Jan 07, 2019 8:30am EST

OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors

Dec 21, 2018 8:30am EST

OncoSec Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies with TAVO™ Directly Activating TILs in Patients

Dec 18, 2018 8:30am EST

OncoSec Reports Updated Tumor Responses in KEYNOTE-695 Study of TAVO™ + KEYTRUDA® in Refractory Metastatic Melanoma

Dec 12, 2018 8:00am EST

OncoSec Presents New Data Showing A Single Cycle Of Monotherapy TAVO™ Can Generate Productive Immune Responses In Triple Negative Breast Cancers (TNBC)

Dec 11, 2018 8:30am EST